title: [Reversion of multidrug resistance in vitro of lung adenocarcinoma by mdr1 ribozyme].
abstract: OBJECTIVE
  To investigate the possibility of reversion of multidrug resistant (MDR) in lung adenocarcinoma-resistant cell line A549/R by mdr1 ribozyme.
  
  
  METHODS
  With GUC at 880 site of mdr1 mRNA selected as target point, plasmid expressing mdr1 ribozyme (pH beta Apr-1 neo/mdr1-Rb) was transduced to A549/R by lipofectin. The expression of mdr1 mRNA and Pgp, cellular rhodamine accumulation and sensitivity to doxorubicin were examined in ribozyme transduced and non-transduced cells.
  
  
  RESULTS
  Transduction of mdr1 ribozyme to A549/R cells led to decrease in mdr1 mRNA and Pgp expression; increase in rhodamine accumulation. The sensitivity of the ribozyme transduced cells to doxorubicin was 200-fold as high as that of the parental drug-resistant cells.
  
  
  CONCLUSIONS
  MDR of lung adenocarcinoma-resistant cell line A549/R can be effectively reversed with mdr1 ribozyme by cleavage of mdr1 mRNA and inhibition of Pgp expression.
authors.affiliation: Department of Respiratory Medicine, General Hospital of PLA, Beijing 100853, China.
authors.forename: L
authors.initials: L
authors.lastname: Chen
authors.forename: Y
authors.initials: Y
authors.lastname: Liu
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism*; D000230:Adenocarcinoma; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D004317:Doxorubicin / Q000494:pharmacology; D018432:Drug Resistance, Multiple / Q000502:physiology*; D004357:Drug Synergism; D006801:Humans; D008175:Lung Neoplasms; D016337:RNA, Catalytic / Q000494:pharmacology*; D012333:RNA, Messenger / Q000187:drug effects / Q000378:metabolism; D014407:Tumor Cells, Cultured
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000970:Antineoplastic Agents; D016337:RNA, Catalytic; D012333:RNA, Messenger; D004317:Doxorubicin